Avatar

About Jennifer Havlek

This author has not yet filled in any details.
So far Jennifer Havlek has created 46 blog entries.
26 Mar, 2021

Biomarker Discovery Solutions for Lymphoma and Multiple Myeloma

Biomarker Discovery Solutions for Lymphoma and Multiple Myeloma Comprehensive Characterization of Genetic Events With Combinatorial DNA and RNA Profiling The ImmunoID NeXT Platform® offers customers an optimized assay by combining highly-sensitive, exome-scale DNA and RNA sequencing, along with fully integrated advanced analytics to provide a multidimensional view of the [...]

1 Feb, 2021

Introduction to Liquid Biopsies

Introduction to Liquid Biopsies Maik M. Pruess, PhD Sr. Field Application Scientist The liquid biopsy is a relatively new concept that has gained traction over the last several years. Circulating tumor DNA (ctDNA) fragments are released by tumor cells into the blood, and contain [...]

1 Feb, 2021

Current Challenges in Liquid Biopsies

Current Challenges in Liquid Biopsies Maik M. Pruess, PhD Sr. Field Application Scientist The liquid biopsy has the potential to change cancer research and clinical care through a variety of applications, from early detection and monitoring, to detection of drug resistance and minimal residual [...]

27 Jan, 2021

NeXT Liquid Biopsy

NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Complementing Tumor Tissue Profiling with Plasma-based Global Resolution NeXT Liquid Biopsy™, a high-performance, exome-wide liquid biopsy assay, is designed to complement Personalis’ flagship tissue-based immunogenomics platform, ImmunoID NeXT™, to further enhance the development of [...]

15 Jul, 2020

John Lyle, PhD

Dr. Lyle joined Personalis in 2020 to manage the company’s assay research and development efforts.  Prior to assuming this role, he spent 14 years at Pacific Biosciences where he most recently served as Senior Director of Single Molecule Sequencing focusing on reagent, system, and application development of long-read, ultra-high accuracy sequencing. Dr. Lyle received his [...]

7 Jul, 2020

2020 AACR: Enhanced Whole Exome Profiling of Tumor Circulating Cell-Free DNA Enables Sensitive Assessment of Tumor Mutations

2020 AACR: Enhanced Whole Exome Profiling of Tumor Circulating Cell-Free DNA Enables Sensitive Assessment of Tumor Mutations An increasing number of studies have demonstrated the potential use of circulating cell-free DNA (cfDNA) for diagnosis, prognosis, and disease progression monitoring. However, many of these studies utilize assays covering a limited set of well known genes, [...]

7 Jul, 2020

2020 AACR: Improved Tumor-Only Somatic Variant Calling Using a Gradient Boosted Machine Learning Algorithm

2020 AACR: Improved Tumor-Only Somatic Variant Calling Using a Gradient Boosted Machine Learning Algorithm Accurate identification of somatic variants in a tumor sample is often accomplished by utilizing a paired normal tissue sample from the same patient to enable the separation of private germline mutations from somatic variants. However, a paired normal sample is [...]

7 Jul, 2020

2020 AACR: A diagnostic platform for precision cancer therapy enabling composite biomarkers by combining tumor and immune features from an enhanced exome and transcriptome

2020 AACR: A diagnostic platform for precision cancer therapy enabling composite biomarkers by combining tumor and immune features from an enhanced exome and transcriptome While the success of immune checkpoint blockade (ICB) has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies requires a more comprehensive approach to tumor immunogenomic profiling. There [...]

7 Jul, 2020

2020 AACR: A Pan-Cancer Characterization of Both the Tumor and Micro Environment Highlights the Importance of an Integrated Approach for Immuno-Oncology

2020 AACR: A Pan-Cancer Characterization of Both the Tumor and Micro Environment Highlights the Importance of an Integrated Approach for Immuno-Oncology A better understanding of the characteristics of cancer across different indications is required to drive the development of personalized treatments, inform therapy decisions, and improve outcomes. Integrating data from the tumor and the [...]

Go to Top